poisar

Stock

Spruce Biosciences, Inc. SPRB

$41.45-0.36%

Overview

SPRB market data

Price History

SPRB price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$50.80
Diluted earnings per share over the trailing twelve months.
Beta
3.48
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$7.00 – $240.00
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $114.1 · P/B 2.19 · P/S 23.23.

Company News

9 captured
8-K filing — SPRUCE BIOSCIENCES, INC. (SPRB)SEC EDGAR · Jul 27, 2026, 12:05 PM
B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160Benzinga · Jul 13, 2026, 1:07 PM
Spruce Biosciences Joins Russell 3000 Index, Effective June 29Benzinga · Jun 29, 2026, 12:10 PM
Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123Benzinga · Jun 16, 2026, 12:40 PM
Jones Trading Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $135Benzinga · Jun 9, 2026, 1:10 PM
Spruce Biosciences Presents Data Demonstrating Long-Term Benefit Of Tralesinidase Alfa Enzyme Replacement Therapy In Patients With Sanfilippo Syndrome Type B At 18th International MPS SymposiumBenzinga · Jun 8, 2026, 8:15 PM
HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $150Benzinga · Jun 1, 2026, 11:03 AM
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $150Benzinga · May 14, 2026, 2:17 PM
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q1 EPS $(8.94) Misses $(8.78) EstimateBenzinga · May 13, 2026, 12:11 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock